Whitehawk Deal History & Licensing Activity
Whitehawk is a life sciences. Over the past three years, Whitehawk has been involved in 2 licensing and acquisition transactions, with a primary focus on ADC (4 deals). The company currently has 2 active clinical trials, primarily in Mega Deals.
Deals (12mo)
2
Active Trials
2
Top Modality
ADC
Focus Area
Mega Deals
Whitehawk Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Whitehawk in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Five-ADC portfolio | Biocytogen | ADC | Preclinical | license | Jul 9, 2026 |
| five ADC candidates (undisclosed) | Biocytogen | ADC | Unknown | license | Jul 9, 2026 |
Whitehawk Pipeline Focus
Therapeutic areas and modalities where Whitehawk is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Whitehawk Strategic Signals
Key indicators of Whitehawk's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Whitehawk Clinical Pipeline
Whitehawk has 2 active clinical trials across 1 development phase.
2
Phase 1
See How Your Asset Matches Whitehawk's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Mega Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Whitehawk Licensing & Deal Activity
Whitehawk is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Whitehawk ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Whitehawk include Mega Deals (4 deals and trials), and Solid Tumors (2 deals and trials). In terms of modality, Whitehawk has shown particular interest in adc.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Whitehawk and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Whitehawk's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.